
Stability, speed and strategy: Inside Australia’s early‑stage edge
In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Jerome Barley, Commercial Director, Avion Medical Ryan Klein, Vice President, Business Development, US and APAC, Resolian Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Publisher
BioSpace
Published
October 29, 2026
Duration
21 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
BioSpace
@biospace
#stability #australiasearly #stageedge #lifesciences
